These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

267 related articles for article (PubMed ID: 38638376)

  • 1. Effects of the Pituitary-targeted Gland Axes on Hepatic Lipid Homeostasis in Endocrine-associated Fatty Liver Disease-A Concept Worth Revisiting.
    Li Y; Zheng M; Limbara S; Zhang S; Yu Y; Yu L; Jiao J
    J Clin Transl Hepatol; 2024 Apr; 12(4):416-427. PubMed ID: 38638376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic lipid accumulation: cause and consequence of dysregulated glucoregulatory hormones.
    Geisler CE; Renquist BJ
    J Endocrinol; 2017 Jul; 234(1):R1-R21. PubMed ID: 28428362
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists.
    Sinha RA; Bruinstroop E; Singh BK; Yen PM
    Thyroid; 2019 Sep; 29(9):1173-1191. PubMed ID: 31389309
    [No Abstract]   [Full Text] [Related]  

  • 4. Tetrahydropalmatine ameliorates hepatic steatosis in nonalcoholic fatty liver disease by switching lipid metabolism via AMPK-SREBP-1c-Sirt1 signaling axis.
    Yin X; Liu Z; Wang J
    Phytomedicine; 2023 Oct; 119():155005. PubMed ID: 37562090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Free radical biology for medicine: learning from nonalcoholic fatty liver disease.
    Serviddio G; Bellanti F; Vendemiale G
    Free Radic Biol Med; 2013 Dec; 65():952-968. PubMed ID: 23994574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ectopic lipid metabolism in anterior pituitary dysfunction.
    Baumgartner C; Krššák M; Vila G; Krebs M; Wolf P
    Front Endocrinol (Lausanne); 2023; 14():1075776. PubMed ID: 36860364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amelioration of non-alcoholic fatty liver disease by targeting adhesion G protein-coupled receptor F1 (
    Wu M; Lo TH; Li L; Sun J; Deng C; Chan KY; Li X; Yeh ST; Lee JTH; Lui PPY; Xu A; Wong CM
    Elife; 2023 Aug; 12():. PubMed ID: 37580962
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease.
    Xi Y; Li H
    Biomed Pharmacother; 2020 Jan; 121():109609. PubMed ID: 31731192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innate immune regulatory networks in hepatic lipid metabolism.
    Bai L; Li H
    J Mol Med (Berl); 2019 May; 97(5):593-604. PubMed ID: 30891617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesencephalic astrocyte-derived neurotrophic factor ameliorates steatosis in HepG2 cells by regulating hepatic lipid metabolism.
    He M; Wang C; Long XH; Peng JJ; Liu DF; Yang GY; Jensen MD; Zhang LL
    World J Gastroenterol; 2020 Mar; 26(10):1029-1041. PubMed ID: 32205994
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Thyroid Hormones on Lipid Metabolism Pathologies in Non-Alcoholic Fatty Liver Disease.
    Liao CJ; Huang PS; Chien HT; Lin TK; Yeh CT; Lin KH
    Biomedicines; 2022 May; 10(6):. PubMed ID: 35740254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insight into Potential Interactions of Thyroid Hormones, Sex Hormones and Their Stimulating Hormones in the Development of Non-Alcoholic Fatty Liver Disease.
    Fröhlich E; Wahl R
    Metabolites; 2022 Aug; 12(8):. PubMed ID: 36005590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thyroid hormone regulation of hepatic lipid and carbohydrate metabolism.
    Sinha RA; Singh BK; Yen PM
    Trends Endocrinol Metab; 2014 Oct; 25(10):538-45. PubMed ID: 25127738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteomic analysis reveals exercise training induced remodelling of hepatokine secretion and uncovers syndecan-4 as a regulator of hepatic lipid metabolism.
    De Nardo W; Miotto PM; Bayliss J; Nie S; Keenan SN; Montgomery MK; Watt MJ
    Mol Metab; 2022 Jun; 60():101491. PubMed ID: 35381388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolic-associated fatty liver disease and lipoprotein metabolism.
    Heeren J; Scheja L
    Mol Metab; 2021 Aug; 50():101238. PubMed ID: 33892169
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduction of hepatic steatosis in rats and mice after treatment with a liver-targeted thyroid hormone receptor agonist.
    Cable EE; Finn PD; Stebbins JW; Hou J; Ito BR; van Poelje PD; Linemeyer DL; Erion MD
    Hepatology; 2009 Feb; 49(2):407-17. PubMed ID: 19072834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolactin improves hepatic steatosis via CD36 pathway.
    Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
    J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exposure to low-intensity noise exacerbates nonalcoholic fatty liver disease by activating hypothalamus pituitary adrenal axis.
    Luo J; Yan Z; Shen Y; Liu D; Su M; Yang J; Xie J; Gao H; Yang J; Liu A
    Sci Total Environ; 2024 Jan; 906():167395. PubMed ID: 37774888
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Models of non-Alcoholic Fatty Liver Disease and Potential Translational Value: the Effects of 3,5-L-diiodothyronine.
    Grasselli E; Canesi L; Portincasa P; Voci A; Vergani L; Demori I
    Ann Hepatol; 2017; 16(5):707-719. PubMed ID: 28809727
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.